Last 32 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.00 | 10.96 | 3963.15 | 268870.91 | 163500.54 | 1893824.81 | 4086688.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -100.0% | -99.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.00 | — | 1.70 | — | 54.74 | 489.19 | 6263.39 | 119429.20 | 314300.04 | 170236.47 | 82192.04 | — | — | 70997444.09 | 826971.03 | 293917.32 | 40683441.82 | 9469956.53 | 4364082.69 | 1857260.13 | 2462887.94 |
| — | — | -100.0% | — | -100.0% | -99.7% | -92.4% | — | — | -99.8% | -90.1% | — | — | +649.7% | -81.1% | -84.2% | +1551.9% | +643.1% | +270.4% | +117.8% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 8.4% | 23.6% | -7.3% | 2.1% | -0.1% | 27.9% | -2136.4% | -6721.4% | 47.8% | 17.4% | -251.6% | 14.1% | 15.9% | 18.4% | 8.3% | 27.7% | 18.6% | 10.6% | 25.8% | — | — |
| — | -15.5% | +99.7% | +100.0% | -100.2% | +60.1% | -749.0% | -47738.1% | +199.4% | -5.1% | -3126.7% | -49.0% | -14.1% | +73.9% | -67.7% | — | — | — | — | — | — | |
| Operating Margin | -612542.2% | -35873.5% | -1098725.6% | -419870.3% | -612788.3% | -550895.4% | -177985.3% | -68588.2% | -13497.1% | -14477.5% | -9780.2% | -6502.9% | -1916.2% | -2647.3% | -4418.2% | -1668.8% | -2687.7% | -2909.0% | -22843.8% | — | — |
| — | +93.5% | -517.3% | -512.2% | -4440.1% | -3705.2% | -1719.9% | -954.7% | -604.4% | -446.9% | -121.4% | -289.7% | +28.7% | +9.0% | +80.7% | — | — | — | — | — | — | |
| Net Margin | -1305608.8% | -131159.8% | -1106277.4% | -3214626.3% | -722789.6% | -560934.1% | -164618.2% | -101262.2% | -17051.3% | -18486.1% | -13491.3% | -7828.9% | -2571.3% | -2740.2% | -4409.1% | -2338.9% | -2724.5% | -2881.5% | -22899.8% | — | — |
| — | +76.6% | -572.0% | -3074.6% | -4138.9% | -2934.4% | -1120.2% | -1193.4% | -563.1% | -574.6% | -206.0% | -234.7% | +5.6% | +4.9% | +80.7% | — | — | — | — | — | — |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -681.6% | — | -118.9% | -1533.7% | -52.3% | -47.5% | -82.1% | -128.6% | -93.6% | -114.1% | -185.5% | — | — | -226.9% | -91.4% | -107.5% | -192.3% | -81.3% | -207.8% | -103.1% | -71.3% |
| — | — | -44.9% | -1092.4% | +44.2% | +58.4% | +55.8% | — | — | +49.7% | -102.9% | — | — | -179.1% | +56.0% | -4.3% | -169.8% | -42.6% | -449.4% | -88.5% | — | |
| ROA | -171.4% | -104.8% | -33.2% | -108.1% | -22.7% | -18.0% | -16.9% | -23.8% | -26.8% | -40.6% | -41.5% | -125.6% | -76.1% | -65.2% | -54.7% | -50.5% | -51.9% | -42.6% | -132.7% | -55.0% | -36.4% |
| — | -481.7% | -96.9% | -353.3% | +15.3% | +55.6% | +59.4% | +81.0% | +64.8% | +37.7% | +24.1% | -148.6% | -46.6% | -53.0% | +58.8% | +8.2% | -42.5% | -3.8% | -303.5% | -60.2% | +71.9% | |
| ROIC | -161.9% | — | -1694.6% | -34.1% | -25.3% | -24.9% | -29.6% | -24.7% | -27.9% | -33.3% | -34.3% | -551.8% | -114.9% | -89.1% | -95.9% | -67.7% | -73.0% | -65.7% | -186.4% | -49.9% | -96.8% |
| — | — | -5618.4% | -38.0% | +9.6% | +25.1% | +13.7% | +95.5% | +75.7% | +62.6% | +64.2% | -714.6% | -57.3% | -35.6% | +48.6% | -35.6% | +24.6% | +61.6% | +5.0% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.76 | — | 0.76 | — | 0.46 | 0.26 | 0.84 | 2.27 | 1.27 | 0.83 | 1.14 | — | — | 60.88 | 0.65 | 0.28 | 3.21 | 0.91 | 0.46 | 0.37 | 1.44 |
| — | — | -8.9% | — | -63.9% | -68.7% | -26.4% | — | — | -98.6% | +74.8% | — | — | +6556.9% | +40.1% | -23.8% | +122.6% | +83.6% | +178.0% | +324.7% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.31 | 0.06 | 0.31 | 0.02 | 0.02 | 0.08 | 0.09 | 0.09 | 0.07 | 0.09 | 0.27 | 0.30 | 0.22 | 0.33 | 1.30 | 2.89 | 0.52 | 0.98 | 2.61 | 3.44 | 1.90 |
| — | -20.8% | +266.0% | -76.3% | -71.2% | -12.8% | -68.0% | -71.9% | -66.8% | -72.0% | -79.5% | -89.4% | -57.3% | -66.6% | -50.1% | -16.1% | -72.8% | -77.4% | -71.0% | -81.8% | +10860.4% | |
| Quick Ratio | 0.31 | 0.05 | 0.31 | 0.02 | 0.02 | 0.08 | 0.08 | 0.08 | 0.05 | 0.06 | 0.24 | 0.23 | 0.12 | 0.20 | 1.04 | 2.56 | 0.33 | 0.75 | 2.47 | 3.44 | 1.90 |
| — | -32.2% | +267.6% | -75.6% | -54.8% | +42.0% | -64.3% | -64.1% | -60.5% | -71.8% | -77.1% | -91.1% | -64.6% | -73.5% | -57.9% | -25.7% | -82.8% | -82.7% | -72.5% | -81.8% | +10860.4% | |
| Interest Coverage | -16.92 | -311.39 | -13.54 | -57.94 | -4.87 | -15.64 | -16.84 | -2.06 | -3.63 | -3.76 | -2.57 | -4.90 | -2.92 | -27.25 | -790.64 | -2.47 | -67.78 | -397.37 | -161.49 | -6.94 | -14.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADTX stock.
Aditxt, Inc.'s current P/E is 0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aditxt, Inc.'s current operating margin is -612542.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aditxt, Inc.'s business trajectory between earnings reports.